Project Grant R03NS148838
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Regents of the University of California, San Francisco a Project Grant totaling $1,179,715 (Award Date: March 15, 2026; Completion Date: January 31, 2034) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The grant supports fundamental research investigating nociception—the mechanisms by which sensory nerve fibers...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant of $531,368 to The Regents of the University of California, San Francisco, with an award date of August 1, 2025, and completion date of July 31, 2027. This award funds research under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The research investigates sex-dependent control of nociception by meningeal...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant of $226,530 to The Regents of the University of California, San Francisco under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) effective August 1, 2025, through July 31, 2030. This K23 Career Development Award supports research investigating precision medicine approaches to chronic neuropathic pain through non-invasive...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of North Carolina at Chapel Hill a $222,758 Project Grant on August 7, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research through July 31, 2027. The award funds a comprehensive neuroscience investigation aimed at delineating how different molecularly defined dorsal root ganglia (DRG) neuron types contribute to pain representation...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded a $4.04 million Project Grant to the University of Texas at Dallas for a three-year initiative (September 1, 2025 through August 31, 2028) to identify and validate therapeutic targets for chronic pain treatment. The project leverages a CRISPR-based functional genomic screening platform developed by collaborating researchers at the University of Sydney and an extensive human dorsal root ganglion...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $246,000 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective September 1, 2025, with a completion date of August 31, 2027. This award funds research investigating pain mechanisms in the female reproductive tract, specifically examining serotonergic and purinergic signaling pathways that mediate...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $646,936 to The Regents of the University of California, San Francisco under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program on June 1, 2026. The five-year project, concluding May 31, 2031, will deliver research products investigating the inflammatory mechanisms underlying spinal cord dysfunction in polytraumatic spinal cord injury (SCI)...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of California, San Francisco a $1.62 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research on the neural mechanisms supporting sudden insight learning in cue-reward associations. The five-year award, effective July 1, 2025 through March 31, 2030, funds fundamental neuroscience research investigating how distributed brain networks—specifically the...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $407,113 to the University of California, Irvine on August 15, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support development of novel KV7 channel modulators for pain therapy. This R21 exploratory research grant, which concludes July 31, 2027, will establish an empirical foundation for developing therapies targeting...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Regents of the University of California, San Francisco a Project Grant totaling $595,208 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award, effective June 1, 2026, through March 31, 2031, funds a collaborative research initiative investigating striatal synaptic plasticity mechanisms underlying cognitive...
The University of California, San Francisco (UCSF) received a $164,000 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) effective July 1, 2026 through June 30, 2027. This award supports research investigating the role of T cell receptor alpha (TRAC) in regulating the anti-nociceptive function of regulatory T cells (Tregs) in neuropathic pain. The research deliverables include investigations into how antigen-specific Treg activation and TRAC-mediated signaling suppress pain through endogenous opioid peptide release, with the ultimate goal of identifying novel, non-addictive therapeutic targets aligned with the NIH HEAL (Helping to End Addiction Long-term) Initiative. The project comprises two primary research aims to be conducted at UCSF's San Francisco facility. Aim 1 delivers single-cell RNA and T cell receptor sequencing analyses to define clonal dynamics of TRAC-expressing Tregs in meninges and injured nerves following spared nerve injury in mice, with identification of clonally expanded enkephalin-producing Tregs linked to pain outcomes. Aim 2 delivers experimental validation using conditional knockout models lacking TRAC in Tregs to assess whether TRAC signaling is required for Treg-mediated analgesia, including measurements of pain behaviors, endogenous opioid levels, and efficacy of Treg expansion therapy. These research deliverables are expected to establish foundational knowledge and biomarkers for immune-based pain therapies addressing chronic neuropathic pain affecting millions of Americans.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $164.0k | 6/12/26 |